Treatment of generalized convulsive status epilepticus in pediatric patients

Journal of Pediatric Pharmacology and Therapeutics

Volumn 20, Issue 4, 2015, Pages 260-289

  Alford, Elizabeth L ^a,b   Wheless, James W ^a,c,d   Phelps, Stephanie J ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Center for Pediatric Pharmacokinetics and Therapeutics   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d Department of Pediatrics   (United States)

Author keywords

Anticonvulsants; Pediatrics; Status epilepticus

Indexed keywords

EID: 84991621271     PISSN: 15516776     EISSN: 2331348X     Source Type: Journal    
DOI: 10.5863/1551-6776-20.4.260     Document Type: Review

References (212)

1. Huff JS, Morris DL, Kothari RU, Gibbs MA. Emergency department management of patients with seizures: a multicenter study. Acad Emerg Med. 2001;8(6):622-628.
2. Capovilla G, Beccaria F, Beghi E, et al. Treatment of convulsive status epilepticus in childhood: Recommendations of the Italian League Against Epilepsy. Epilepsia. 2013;54(suppl 7):23-34.
3. DeLorenzo RJ, Garnett LK, Towne AR, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia. 1999;40(2):164-169.
4. Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia. 2006;47(9):1499-1503.
5. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120-122.
6. Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last? Ann Neurol. 2001;49(5):659-664.
7. Wasterlain CG, Chen JW. Definition and classification of status epilepticus. In: Westerlain CG, Treiman DM, eds. Status Epilepticus. Cambridge, MA: MIT Press; 2006:11-16.
8. Lothman E. The biochemical basis and pathophysiology of status epilepticus. Neurology. 1990;40 5(suppl 2):13-23.
9. DeLorenzo RJ, Towne AR, Pellock JM, Ko D. Status epilepticus in children, adults, and the elderly. Epilepsia. 1992;33(suppl 4):S15-S25.
10. Singh RK, Gaillard WD. Status epilepticus in children. Curr Neurol Neurosci Rep. 2009;9(2):137-144.
11. Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998;814(1-2):179-185.
12. Chen JW, Naylor DE, Wasterlain CG. Advances in the pathophysiology of status epilepticus. Acta Neurol Scand. 2007;186:7-15.
13. Naylor DE. Glutamate and gaba in the balance: convergent pathways sustain seizures during status epilepticus. Epilepsia. 2010;51(suppl 3):106-109.
14. Goodkin HR, Joshi S, Kozhemyakin M, Kapur J. Impact of receptor changes on treatment of status epilepticus. Epilepsia. 2007;48(suppl 8):14-15.
15. Goodkin HP, Sun C, Yeh JL, et al. Gaba(a) receptor internalization during seizures. Epilepsia. 2007;48(suppl 5):109-113.
16. Wasterlain CG, Chen JW. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia. 2008;49(suppl 9):63-73.
17. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther. 2001;90(1):21-34.
18. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5(3):246-256.
19. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10(7):685-692.
20. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4(1):18-61.
21. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
22. Treatment of convulsive status epilepticus. Recommendations of the epilepsy foundation of america’s working group on status epilepticus. JAMA. 1993;270(7):854-859.
23. Appleton R, Choonara I, Martland T, et al. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, members of the Status Epilepticus Working Party. Arch Dis Child. 2000;83(5):415-419.
24. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 2007;9(4):353-412.
25. Shorvon S, Baulac M, Cross H, et al. The drug treatment of status epilepticus in europe: Consensus document from a workshop at the First London Colloquium on Status Epilepticus. Epilepsia. 2008;49(7):1277-1285.
26. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348-355.
27. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-ofhospital status epilepticus. N Engl J Med. 2001;345(9):631-637.
28. Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249(11):1452-1454.
29. Cock HR, Schapira AH. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM. 2002;95(4):225-231.
30. Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2008(3):Cd001905.
31. Minicucci F, Muscas G, Perucca E, et al. Treatment of status epilepticus in adults: guidelines of the Italian League Against Epilepsy. Epilepsia. 2006;47(suppl 5):9-15.
32. Lahat E, Goldman M, Barr J, et al. Intranasal midazolam for childhood seizures. Lancet. 1998;352(9128):620.
33. Lahat E, Goldman M, Barr J, et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: Prospective randomised study. BMJ. 2000;321(7253):83-86.
34. Fisgin T, Gurer Y, Tezic T, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol. 2002;17(2):123-126.
35. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006;34(5):355-359.
36. Tonekaboni SH, Shamsabadi FM, Anvari SS, et al. A comparison of buccal midazolam and intravenous diazepam for the acute treatment of seizures in children. Iran J Pediatr. 2012;22(3):303-308.
37. Silbergleit R, Lowenstein D, Durkalski V, Conwit R. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52(suppl 8):45-47.
38. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 16 2012;366(7):591-600.
39. Abou-Khalil B, Wheless J, Rogin J, et al. A double-blind, randomized, placebocontrolled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures. Epilepsia. 2013;54(11):1968-1976.
40. Rogin J, Wheless J, Abou-Khalil B, et al. Safety and effectiveness of long-term treatment with diazepam auto-injector administered by caregivers in an outpatient setting for the treatment of acute repetitive seizures. Epilepsia. 2014;55(9):1444-1451.
41. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: A randomised trial. Lancet. 1999;353(9153):623-626.
42. Camfield PR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. J Pediatr. 1999;135(3):398-399.
43. Warden CR, Frederick C. Midazolam and diazepam for pediatric seizures in the prehospital setting. Prehosp Emerg Care. 2006;10(4):463-467.
44. Harbord MG, Kyrkou NE, Kyrkou MR, et al. Use of intranasal midazolam to treat acute seizures in paediatric community settings. J Paediatr Child Health. 2004;40(9-10):556-558.
45. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164(8):747-753.
46. O’Regan ME, Brown JK, Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures? Dev Med Child Neurol. 1996;38(11):1037-1045.
47. Kutlu NO, Yakinci C, Dogrul M, Durmaz Y. Intranasal midazolam for prolonged convulsive seizures. Brain Dev. 2000;22(6):359-361.
48. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253-255.
49. Holsti M, Sill BL, Firth SD, et al. Prehospital intranasal midazolam for the treatment of pediatric seizures. Pediatr Emerg Care. 2007;23(3):148-153.
50. Thakker A, Shanbag P. A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures. J Neurol. 2013;260(2):470-474.
51. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17(6):575-582.
52. Anderson M, Tambe P, Sammons H, et al. Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers. Eur J Clin Pharmacol. 2012;68(2):155-159.
53. Scheepers M, Scheepers B, Clarke M, et al. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? Seizure. 2000;9(6):417-422.
54. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol. 1991;41(4):355-357.
55. Wermeling DP, Miller JL, Archer SM, et al. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol. 2001;41(11):1225-1231.
56. Arya R, Gulati S, Kabra M, et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia. 2011;52(4):788-793.
57. Fisgin T, Gurer Y, Senbil N, et al. Nasal midazolam effects on childhood acute seizures. J Child Neurol. 2000;15(12):833-835.
58. Anderson M. Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2013;7:27-34.
59. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205-210.
60. Mpimbaza A, Ndeezi G, Staedke S, et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008;121(1):e58-64.
61. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev. 2009;31(10):744-749.
62. Khan A, Baheerathan A, Setty G, Hussain N. Carers’ express positive views on the acceptability, efficacy and safety of buccal midazolam for paediatric status epilepticus. Acta Paediatr. 2014;103(4):e165-168.
63. Ivaturi V, Kriel R, Brundage R, et al. Bioavailability of intranasal vs. rectal diazepam. Epilepsy Res. 2013;103(2-3):254-261.
64. Malinovsky JM, Lejus C, Servin F, et al. Plasma concentrations of midazolam after i.V., nasal or rectal administration in children. Br J Anaesth. 1993;70(6):617-620.
65. Knoester PD, Jonker DM, Van Der Hoeven RT, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002;53(5):501-507.
66. Baysun S, Aydin OF, Atmaca E, Gurer YK. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila). 2005;44(9):771-776.
67. Ashrafi MR, Khosroshahi N, Karimi P, et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. Eur J Paediatr Neurol. 2010;14(5):434-438.
68. Anderson GD, Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev. 2012;64(10):911-918.
69. Humphries LK, Eiland LS. Treatment of acute seizures: Is intranasal midazolam a viable option? J Pediatr Pharmacol Ther. 2013;18(2):79-87.
70. Khan TM, Kissoon N, Hasan MY, et al. Comparison of plasma levels and pharmacodynamics after intraosseous and intravenous administration of fosphenytoin and phenytoin in piglets. Pediatr Crit Care Med. 2000;1(1):60-64.
71. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology. 1988;38(2):202-207.
72. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative study group. N Engl J Med. 17 1998;339(12):792-798.
73. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23(3):167-174.
74. Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology. 2005;64(2):353-355.
75. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus—experience in 102 adult patients. Seizure. 2005;14(3):164-169.
76. Olsen KB, Tauboll E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl. 2007;187:51-54.
77. Gilad R, Izkovitz N, Dabby R, et al. Treatment of status epilepticus and acute repetitive seizures with I.V. Valproic acid vs phenytoin. Acta Neurol Scand. 2008;118(5):296-300.
78. Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16(6):527-532.
79. Chen L, Feng P, Wang J, et al. Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. J Clin Neurosci. 2009;16(4):524-526.
80. Hovinga CA, Chicella MF, Rose DF, et al. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Ann Pharmacother. 1999;33(5):579-584.
81. Uberall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 13 2000;54(11):2188-2189.
82. Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia. 2003;44(5):724-726.
83. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: A randomized controlled trial. J Child Neurol. 2007;22(10):1191-1197.
84. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: A pilot study. Neurology. 2006;67(2):340-342.
85. Tiamkao S, Sawanyawisuth K, Chancharoen A. The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study. BMC Neurol. 2013;13:98.
86. Chitsaz A, Mehvari J, Salari M, et al. A comparative assessment the efficacy of intravenous infusion of sodium valproate and phenytion in the treatment of status epilepticus. Int J Prev Med. 2013;4(Suppl 2):S216-221.
87. Malamiri RA, Ghaempanah M, Khosroshahi N, et al. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012;16(5):536-541.
88. Brigo F, Storti M, Del Felice A, et al. IV valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol. 2012;19(9):1180-1191.
89. Brigo F, Igwe SC, Nardone R, et al. A common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone for convulsive status epilepticus. Epileptic Disord. 2013;15(3):314-323.
90. Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav. 2006;8(3):651-654.
91. Patel NC, Landan IR, Levin J, et al. The use of levetiracetam in refractory status epilepticus. Seizure. 2006;15(3):137-141.
92. Rupprecht S, Franke K, Fitzek S, et al. Levetiracetam as a treatment option in nonconvulsive status epilepticus. Epilepsy Res. 2007;73(3):238-244.
93. Goraya JS, Khurana DS, Valencia I, et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol. 2008;38(3):177-180.
94. Abend NS, Monk HM, Licht DJ, Dlugos DJ. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. Pediatr Crit Care Med. 2009;10(4):505-510.
95. Kirmani BF, Crisp ED, Kayani S, Rajab H. Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol. 2009;41(1):37-39.
96. Standish JC, Hilmas E, Falchek SJ. Levetiracetam for the treatment of pediatric status epilepticus: a case series. J Pediatr Neurol. 2011;9(2):195-201.
97. McTague A, Kneen R, Kumar R, et al. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: Experience from a children’s hospital. Seizure. 2012;21(7):529-534.
98. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393-404.
99. Shiloh-Malawsky Y, Fan Z, Greenwood R, Tennison M. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. Seizure. 2011;20(7):586-588.
100. Jain V, Harvey AS. Treatment of refractory tonic status epilepticus with intravenous lacosamide. Epilepsia. 2012;53(4):761-762.
101. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91(4):593-600.
102. Gerstner T, Teich M, Bell N, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47(7):1136-1143.
103. Embacher N, Karner E, Wanschitz J, et al. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol. 2006;13(10):e5-6.
104. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channelblocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20(1):20-23.
105. Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54(suppl 6):89-92.
106. Shinnar S, Pellock JM, Moshe SL, et al. In whom does status epilepticus occur: agerelated differences in children. Epilepsia. 1997;38(8):907-914.
107. Wu YW, Shek DW, Garcia PA, et al. Incidence and mortality of generalized convulsive status epilepticus in california. Neurology. 9 2002;58(7):1070-1076.
108. Moshe SL. Brain injury with prolonged seizures in children and adults. J Child Neurol. 1998;13(suppl 1):S3-S6; discussion S30-32.
109. Sahin M, Menache CC, Holmes GL, Riviello JJ, Jr. Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children. Neurology. 12 2003;61(3):398-401.
110. Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics. 1989;83(3):323-331.
111. Gilbert DL, Gartside PS, Glauser TA. Efficacy and mortality in treatment of refractory generalized convulsive status epilepticus in children: a meta-analysis. J Child Neurol. 1999;14(9):602-609.
112. Sahin M, Menache CC, Holmes GL, Riviello JJ. Outcome of severe refractory status epilepticus in children. Epilepsia. 2001;42(11):1461-1467.
113. Kim SJ, Lee DY, Kim JS. Neurologic outcomes of pediatric epileptic patients with pentobarbital coma. Pediatr Neurol. 2001;25(3):217-220.
114. Fountain NB, Fugate JE. Refractory status epilepticus: what to put down: the anesthetics or the patient? Neurology. 25 2014;82(8):650-651.
115. Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci. 15 2003;211(1-2):37-41.
116. Holtkamp M, Masuhr F, Harms L, et al. The management of refractory generalised convulsive and complex partial status epilepticus in three european countries: a survey among epileptologists and critical care neurologists. J Neurol Neurosurg Psychiatry. 2003;74(8):1095-1099.
117. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43(2):146-153.
118. Young RS, Ropper AH, Hawkes D, et al. Pentobarbital in refractory status epilepticus. Pediatr Pharmacol (New York). 1983;3(2):63-67.
119. Lowenstein DH, Aminoff MJ, Simon RP. Barbiturate anesthesia in the treatment of status epilepticus: Clinical experience with 14 patients. Neurology. 1988;38(3):395-400.
120. Rashkin MC, Youngs C, Penovich P. Pentobarbital treatment of refractory status epilepticus. Neurology. 1987;37(3):500-503.
121. Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology. 1993;43(5):895-900.
122. Kinoshita H, Nakagawa E, Iwasaki Y, et al. Pentobarbital therapy for status epilepticus in children: Timing of tapering. Pediatr Neurol. 1995;13(2):164-168.
123. Holmes GL, Riviello JJ Jr. Midazolam and pentobarbital for refractory status epilepticus. Pediatr Neurol. 1999;20(4):259-264.
124. Barberio M, Reiter PD, Kaufman J, et al. Continuous infusion pentobarbital for refractory status epilepticus in children. J Child Neurol. 2012;27(6):721-726.
125. Mirski MA, Williams MA, Hanley DF. Prolonged pentobarbital and phenobarbital coma for refractory generalized status epilepticus. Crit Care Med. 1995;23(2):400-404.
126. Lee WK, Liu KT, Young BW. Very-highdose phenobarbital for childhood refractory status epilepticus. Pediatr Neurol. 2006;34(1):63-65.
127. Osorio I, Reed RC. Treatment of refractory generalized tonic-clonic status epilepticus with pentobarbital anesthesia after highdose phenytoin. Epilepsia. 1989;30(4):464-471.
128. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia. 1996;37(9):863-867.
129. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62(11):1698-1702.
130. Schreiber JM, Gaillard WD. Treatment of refractory status epilepticus in childhood. Curr Neurol Neurosci Rep. 2011;11(2):195-204.
131. Van Ness PC. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia. 1990;31(1):61-67.
132. Chicella M, Jansen P, Parthiban A, et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Crit Care Med. 2002;30(12):2752-2756.
133. Bledsoe KA, Kramer AH. Propylene glycol toxicity complicating use of barbiturate coma. Neurocrit Care. 2008;9(1):122-124.
134. Miller MA, Forni A, Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. Ann Pharmacother. 2008;42(10):1502-1506.
135. Barnes BJ, Gerst C, Smith JR, et al. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy. 2006;26(1):23-33.
136. Parker MG, Fraser GL, Watson DM, Riker RR. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med. 2002;28(1):81-84.
137. Zar T, Yusufzai I, Sullivan A, Graeber C. Acute kidney injury, hyperosmolality and metabolic acidosis associated with lorazepam. Nat Clin Pract Nephrol. 2007;3(9):515-520.
138. Rivera R, Segnini M, Baltodano A, Perez V. Midazolam in the treatment of status epilepticus in children. Crit Care Med. 1993;21(7):991-994.
139. Koul RL, Raj Aithala G, Chacko A, et al. Continuous midazolam infusion as treatment of status epilepticus. Arch Dis Child. 1997;76(5):445-448.
140. Igartua J, Silver P, Maytal J, Sagy M. Midazolam coma for refractory status epilepticus in children. Crit Care Med. 1999;27(9):1982-1985.
141. Ozdemir D, Gulez P, Uran N, et al. Efficacy of continuous midazolam infusion and mortality in childhood refractory generalized convulsive status epilepticus. Seizure. 2005;14(2):129-132.
142. Morrison G, Gibbons E, Whitehouse WP. High-dose midazolam therapy for refractory status epilepticus in children. Intensive Care Med. 2006;32(12):2070-2076.
143. Koul R, Chacko A, Javed H, Al Riyami K. Eight-year study of childhood status epilepticus: Midazolam infusion in management and outcome. J Child Neurol. 2002;17(12):908-910.
144. Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17(2):106-110.
145. Hayashi K, Osawa M, Aihara M, et al. Efficacy of intravenous midazolam for status epilepticus in childhood. Pediatr Neurol. 2007;36(6):366-372.
146. Claassen J, Hirsch LJ, Emerson RG, et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology. 25 2001;57(6):1036-1042.
147. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314-2328.
148. Fernandez A, Lantigua H, Lesch C, et al. High-dose midazolam infusion for refractory status epilepticus. Neurology. 28 2014;82(4):359-365.
149. Wilkes R, Tasker RC. Pediatric intensive care treatment of uncontrolled status epilepticus. Crit Care Clin. 2013;29(2):239-257.
150. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med. 1992;20(4):483-488.
151. Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology. 2000;54(6):1366-1368.
152. Harrison AM, Lugo RA, Schunk JE. Treatment of convulsive status epilepticus with propofol: case report. Pediatr Emerg Care. 1997;13(6):420-422.
153. Brown LA, Levin GM. Role of propofol in refractory status epilepticus. Ann Pharmacother. 1998;32(10):1053-1059.
154. Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: A study of 31 episodes. Epilepsia. 2004;45(7):757-763.
155. Parviainen I, Uusaro A, Kalviainen R, et al. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006;32(7):1075-1079.
156. Rossetti AO, Milligan TA, Vulliemoz S, et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14(1):4-10.
157. van Gestel JP, Blusse van Oud-Alblas HJ, Malingre M, et al. Propofol and thiopental for refractory status epilepticus in children. Neurology. 2005;65(4):591-592.
158. Timpe EM, Eichner SF, Phelps SJ. Propofolrelated infusion syndrome in critically ill pediatric patients: Coincidence, association, or causation? J Pediatr Pharmacol Ther. 2006;11(1):17-42.
159. Barclay K, Williams AJ, Major E. Propofol infusion in children. BMJ. 1992;305(6859):953; author reply 953-954.
160. Cray SH, Robinson BH, Cox PN. Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med. 1998;26(12):2087-2092.
161. Wolf A, Weir P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet. 24 2001;357(9256):606-607.
162. Withington DE, Decell MK, Al Ayed T. A case of propofol toxicity: Further evidence for a causal mechanism. Paediatr Anaesth. 2004;14(6):505-508.
163. Culp KE, Augoustides JG, Ochroch AE, Milas BL. Clinical management of cardiogenic shock associated with prolonged propofol infusion. Anesth Analg. 2004;99(1):221-226.
164. Guitton C, Gabillet L, Latour P, et al. Propofol infusion syndrome during refractory status epilepticus in a young adult: Successful ecmo resuscitation. Neurocrit Care. 2011;15(1):139-145.
165. Mayette M, Gonda J, Hsu JL, Mihm FG. Propofol infusion syndrome resuscitation with extracorporeal life support: A case report and review of the literature. Ann Intensive Care. 2013;3(1):32.
166. Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37(12):3024-3030.
167. Baumeister FA, Oberhoffer R, Liebhaber GM, et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics. 2004;35(4):250-252.
168. Voss LJ, Sleigh JW, Barnard JP, Kirsch HE. The howling cortex: seizures and general anesthetic drugs. Anesth Analg. 2008;107(5):1689-1703.
169. Walder B, Tramer MR, Seeck M. Seizurelike phenomena and propofol: a systematic review. Neurology. 2002;58(9):1327-1332.
170. Zubair S, Patton T, Smithson K, et al. Propofol withdrawal seizures: Non-epileptic nature of seizures in a patient with recently controlled status epilepticus. Epileptic Disord. 2011;13(1):107-110.
171. Dorandeu F, Dhote F, Barbier L, et al. Treatment of status epilepticus with ketamine, are we there yet? CNS Neurosci Ther. 2013;19(6):411-427.
172. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51(6):1765-1766.
173. Rosati A, L’Erario M, Ilvento L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology. 2012;79(24):2355-2358.
174. Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498-1503.
175. Gofrit ON, Leibovici D, Shemer J, et al. Ketamine in the field: The use of ketamine for induction of anaesthesia before intubation in injured patients in the field. Injury. 1997;28(1):41-43.
176. Kofke WA, Young RS, Davis P, et al. Isoflurane for refractory status epilepticus: a clinical series. Anesthesiology. 1989;71(5):653-659.
177. Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol. 2004;61(8):1254-1259.
178. Fugate JE, Burns JD, Wijdicks EF, et al. Prolonged high-dose isoflurane for refractory status epilepticus: Is it safe? Anesth Analg. 2010;111(6):1520-1524.
179. Visser NA, Braun KP, Leijten FS, et al. Magnesium treatment for patients with refractory status epilepticus due to polg1-mutations. J Neurol. 2011;258(2):218-222.
180. Kahriman M, Minecan D, Kutluay E, et al. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia. 2003;44(10):1353-1356.
181. Blumkin L, Lerman-Sagie T, Houri T, et al. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol. 2005;20(3):239-241.
182. Akyildiz BN, Kumandas S. Treatment of pediatric refractory status epilepticus with topiramate. Childs Nerv Syst. 2011;27(9):1425-1430.
183. Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia. 2006;47(6):1070-1071.
184. Bragatti JA, Torres CM, Netto CB, et al. Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency. Arq Neuropsiquiatr. 2011;69(3):565-566.
185. Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia. 2001;42(3):387-392.
186. Ozer Y, Altunkaya H. Topiramate induced metabolic acidosis. Anaesthesia. 2004;59(8):830.
187. Fakhoury T, Murray L, Seger D, et al. Topiramate overdose: clinical and laboratory features. Epilepsy Behav. 2002;3(2):185-189.
188. Lynch MJ, Pizon AF, Siam MG, Krasowski MD. Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. J Med Toxicol. 2010;6(2):135-138.
189. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802-2818.
190. Wheless JW. Treatment of refractory convulsive status epilepticus in children: other therapies. Semin Pediatr Neurol. 2010;17(3):190-194.
191. Rogawski MA, Loya CM, Reddy K, et al. Neuroactive steroids for the treatment of status epilepticus. Epilepsia. 2013;54(suppl 6):93-98.
192. Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in rasmussen’s encephalitis. Neurology. 2003;61(12):1807-1810.
193. Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (Norse) syndrome: outcomes with early immunotherapy. Seizure. 2013;22(3):217-220.
194. Schmitt FC, Buchheim K, Meierkord H, Holtkamp M. Anticonvulsant properties of hypothermia in experimental status epilepticus. Neurobiol Dis. 2006;23(3):689-696.
195. Orlowski JP, Erenberg G, Lueders H, Cruse RP. Hypothermia and barbiturate coma for refractory status epilepticus. Crit Care Med. 1984;12(4):367-372.
196. Corry JJ, Dhar R, Murphy T, Diringer MN. Hypothermia for refractory status epilepticus. Neurocrit Care. 2008;9(2):189-197.
197. Rossetti AO. What is the value of hypothermia in acute neurologic diseases and status epilepticus? Epilepsia. 2011;52(suppl 8):64-66.
198. Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome p450 enzyme system. Crit Care Med. 2007;35(9):2196-2204.
199. Empey PE, de Mendizabal NV, Bell MJ, et al. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Crit Care Med. 2013;41(10):2379-2387.
200. Weiner RD, Coffet CE, Fochtmann L. The Practice of ECT: Recommendations for Treatment, Training and Privileging. 2nd ed. Washington, DC: American Psychiatric Press; 2001.
201. Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. J ECT. 1999;15(1):5-26.
202. Lambrecq V, Villega F, Marchal C, et al. Refractory status epilepticus: electroconvulsive therapy as a possible therapeutic strategy. Seizure. 2012;21(9):661-664.
203. Cervenka MC, Hartman AL, Venkatesan A, et al. The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. Neurocrit Care. 2011;15(3):519-524.
204. Cobo NH, Sankar R, Murata KK, et al. The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: challenges in implementation in the pediatric and neonatal intensive care units. J Child Neurol. 2014.
205. Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia. 2010;51(10):2033-2037.
206. Nam SH, Lee BL, Lee CG, et al. The role of ketogenic diet in the treatment of refractory status epilepticus. Epilepsia. 2011;52(11):e181-184.
207. Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in superrefractory status epilepticus. Neurology. 25 2014;82(8):665-670.
208. Winston KR, Levisohn P, Miller BR, Freeman J. Vagal nerve stimulation for status epilepticus. Pediatr Neurosurg. 2001;34(4):190-192.
209. Patwardhan RV, Dellabadia J, Jr., Rashidi M, et al. Control of refractory status epilepticus precipitated by anticonvulsant withdrawal using left vagal nerve stimulation: a case report. Surg Neurol. 2005;64(2):170-173.
210. O’Neill BR, Valeriano J, Synowiec A, et al. Refractory status epilepticus treated with vagal nerve stimulation: case report. Neurosurgery. 2011;69(5):E1172-1175.
211. Hauptman JS, Mathern GW. Vagal nerve stimulation for pharmacoresistant epilepsy in children. Surg Neurol Int. 2012;3(suppl 4):S269-274.
212. Rossignol E, Lortie A, Thomas T, et al. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure. 2009;18(1):34-37.